Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 54Observational 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Recurrence 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1

Interventions

Rituximab 29Surveys and Questionnaires 25Blood Specimen Collection 17Gene Expression Profiling 15Flow Cytometry 14Polymerase Chain Reaction 13Amplified Fragment Length Polymorphism Analysis 13Microarray Analysis 11Observation 10Interviews as Topic 10Psychiatric Rehabilitation 9Lenalidomide 9Immunohistochemistry 9Cytogenetic Analysis 9obinutuzumab 8Watchful Waiting 8Therapeutics 8ibrutinib 7Drug Therapy 7Cyclophosphamide 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Magnetic Resonance Spectroscopy 6fludarabine 5In Situ Hybridization, Fluorescence 5Immunologic Techniques 5Data Collection 5Biopsy 5zanubrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × romidepsin × Lymphoid × Clear all
NCT03742921 2023-12-06

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Celgene

Completed
150 enrolled
Lymphoid

Recurrence, Lymphoma, T-Cell, Peripheral

NCT02296398 2016-03-11

Long-term Use of Romidepsin in Patients With CTCL

Northwestern University

Completed
47 enrolled
DermatologicLymphoid

Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡